https://doi.org/10.4081/hmr.v1i8.292

Thalidomide analogs

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 175
PDF: 490
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

P Tosi
support@pagepress.org
E Zamagni
D Cangini
P Tacchetti
G Perrone
M Ceccolini
M Cavo
Thalidomide-based regimens have shown remarkable activity in relapsed-refractory multiple myeloma (MM) so that their use has been successfully extended to newly diagnosed patients. Thalidomide-dexamethasone combination has demonstrated to be superior to VAD in terms of both response rate and relative reduction of serum or urine M component,1 and these results are being confirmed in multicenter randomised ongoing trials.2 A major drawback of thalidomide is represented by its side effects; more than half of the patients complain about lethargy and constipation, deep venous thromboses occur in up to 15-20% of newly diagnosed patients treated with thalidomide-dexamethasone unless a proper prophylaxis is performed3-4 grade ≥2 WHO peripheral neuropathy is reported in 60% of the patients treated longer than 1 year;5 the incidence and extent of side effects limit the usage of thalidomide in other hematological conditions such as Waldenstrom macroglobulinemia, AL amyloidosis and, above all, myelofiblosis.1

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Tosi, P., Zamagni, E., Cangini, D., Tacchetti, P., Perrone, G., Ceccolini, M., & Cavo, M. (2009). Thalidomide analogs. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.292
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).